Healthcare spending grew faster than the rest of the economy last year despite the ongoing reduction in hospital use and an industrywide campaign to hold down costs. How can that be?
Mark Ganz, president and CEO of Cambia Health Solutions, a not-for-profit parent of 22 companies offering healthcare products and services, discusses how his companies are seeking to make healthcare more consumer-directed.
David Cade, a former top attorney at HHS, has been appointed CEO of the American Health Lawyers Association.
The soaring sales and profits reported by Gilead Sciences in 2014 aren't likely to be repeated as the company begins to offer steeper discounts on its blockbuster hepatitis C treatments Sovaldi and Harvoni.
Gilead Sciences, the Foster City, Calif.-based drugmaker, said sales of its blockbuster hepatitis C duo topped $3.8 billion in the fourth quarter of 2014, fueling quarterly revenue that doubled to $7.3 billion and $3.5 billion in profits.
Gilead Sciences, the biopharmaceutical company, announced the promotion of two employees to executive vice president positions. Dr. Andrew Cheng has been promoted to executive VP of HIV therapeutics and development operations, and Taiyin Yang has been promoted to executive VP of pharmaceutical...
The pricing battle pitting insurers and pharmacy benefit managers against drugmakers over a new breed of high-priced and highly effective treatments for hepatitis C may be a preview of tougher negotiations for coverage of other blockbuster drugs.
The antiviral medication Tamiflu shortened the length of time patients experienced flu symptoms, and reduced rates of complications and hospitalizations from the virus, a new study finds. But it did not have an effect on those with flu-like symptoms who did not have the flu.
Harvard Pilgrim Health Care, one of the largest not-for-profit health insurers in New England, said it will save millions of dollars in hepatitis C drug costs through its negotiated pricing discount from pharmaceutical giant Gilead Sciences.
The nation's largest healthcare organizations predicted a profitable 2015 at the annual J.P. Morgan Healthcare Conference in San Francisco. They forecast that the biggest cloud on the horizon—the pending U.S. Supreme Court case challenging the Obamacare premium subsidies—would pass...
Aetna has agreed to a deal with Gilead Sciences to give preference to the drugmaker's hepatitis C drugs. It's the fourth straight agreement where a payer or benefits manager has chosen Gilead over competitor AbbVie.
Exclusivity deals for hepatitis C drugs by pharmacy benefit managers and a major health plan have raised concerns that the decision of which drug is best for a patient is being taken away from clinicians.